Skip to Main Content

Lena Winestone

MD MS

Pediatric hematologist-oncologist
Bone marrow transplant specialist
Health disparities researcher

Dr. Lena Winestone is a pediatric blood and bone marrow transplant specialist with a strong interest in caring for children with high-risk or relapsed leukemia or lymphoma. She has a focus on using novel immunotherapies – treatments that improve the body's own ability to fight cancer – so that patients with therapy-resistant leukemia can receive successful transplants.

Winestone's research explores racial, ethnic and socioeconomic disparities in children's access to leukemia treatment, including bone marrow transplant, and in their outcomes. Her top priority is ensuring that all children can get the best possible treatment as early as possible.

After earning a master's degree in chemistry from the University of Pennsylvania, Winestone earned her medical degree at Stanford University School of Medicine. She then completed a residency in pediatrics at Lucile Packard Children's Hospital Stanford and a fellowship in pediatric hematology and oncology at the Children's Hospital of Philadelphia. She also has a master's degree in health policy research from the University of Pennsylvania's Perelman School of Medicine.

Winestone is a member of the Children's Oncology Group, American Society for Transplantation and Cellular Therapy, and American Society of Hematology.

Before coming to UCSF, Winestone worked in a variety of places around the world, including Kenya, Lesotho, South Africa, Switzerland and Nepal. Outside of work, she enjoys pursuing outdoor activities in the Bay Area with her family and traveling abroad.

  • Education

    University of Pennsylvania, MS, Chemistry, 2004

    Stanford University School of Medicine, 2009

    Perelman School of Medicine, MS, Health Policy Research, 2016

  • Residencies

    Stanford Children's Health, Pediatrics, 2012

  • Fellowships

    Children's Hospital of Philadelphia, Pediatric Hematology and Oncology, 2016

  • Academic Title

    Associate Professor

I'm always working toward health equity. My goal is to bring the same innovative approaches and great outcomes to all patients.

Where I see patients (1)

    Decorative Caduceus

    Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children,...

    We will estimate the cumulative incidence of severe GVHD at 1-year post-HCT and corresponding 95% confidence interval among enrolled and eligible patients randomly assigned to either HAPLO or MUD arms who actually undergo HCT.

    Recruiting

    More about this study
    See all clinical trials

    Translation, please

    We have interpreters for Cantonese, Mandarin, Spanish, Russian, American Sign Language and more.

    Request an interpreter

    Share